8-nitroguanidinooctanoic acid | 150638-20-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 8-nitroguanidinooctanoic acid
• 英文别名: 8-[(N'-nitrocarbamimidoyl)amino]octanoic acid
• CAS: 150638-20-3
• 化学式: C₉H₁₈N₄O₄
• 分子量: 246.266
• InChiKey: SMTJJTZTLTZLRV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  17
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  134
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  8-nitroguanidinooctanoic acid 在 palladium on activated charcoal 氢气 、 双(2-氧代-3-恶唑烷基)次磷酰氯 、 三乙胺 作用下， 以 甲醇 、 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 25.0 ℃ 、379.21 kPa 条件下， 反应 14.0h， 生成 (3R)-N-(8-guanidino)octanoyl-N'-(9-guanidino)nonanoyl-3,3-diaminopropionic acid
  参考文献：
  名称：

  Conformationally flexible platelet aggregation inhibitors based on the tetrapeptide Arg-Gly-Asp-Arg

  摘要：

  A series of nonpeptide fibrinogen receptor antagonists based upon the tetrapeptide Arg-Gly-Asp-Arg were prepared. These relatively simple derivatives incorporate a high degree of conformational flexibility that was anticipated to allow them to attain the requisite conformation for binding to the platelet fibrinogen receptor. Optimization of the distances between the required acidic and basic functional groups led eventually to compound 7, which is a one hundred-fold more potent inhibitor of platelet aggregation than the peptide it is based upon.

  DOI：

  10.1016/s0223-5234(99)80069-5
• 作为产物：
  描述：

  8-氨基辛酸 在 硫酸 、 硝酸 、 potassium carbonate 作用下， 以 水 为溶剂， 反应 1.0h， 生成 8-nitroguanidinooctanoic acid
  参考文献：
  名称：

  Conformationally flexible platelet aggregation inhibitors based on the tetrapeptide Arg-Gly-Asp-Arg

  摘要：

  A series of nonpeptide fibrinogen receptor antagonists based upon the tetrapeptide Arg-Gly-Asp-Arg were prepared. These relatively simple derivatives incorporate a high degree of conformational flexibility that was anticipated to allow them to attain the requisite conformation for binding to the platelet fibrinogen receptor. Optimization of the distances between the required acidic and basic functional groups led eventually to compound 7, which is a one hundred-fold more potent inhibitor of platelet aggregation than the peptide it is based upon.

  DOI：

  10.1016/s0223-5234(99)80069-5

文献信息

• Antithrombotic diaminoalkanoic acid derivatives
  申请人：Rhone-Poulenc Rorer Pharmaceuticals Inc.

  公开号：US05258398A1

  公开（公告）日：1993-11-02

  This invention relates to novel diaminoalkanoic acid derivatives that inhibit platelet aggregation and thrombus formation in mammalian blood thereby being useful in the prevention and treatment of thrombosis associated with disease states such as myocardial infarction, stroke, peripheral arterial disease and disseminated intravascular coagulation, to pharmaceutical compositions including such compounds, and to their use in inhibiting thrombus formation and platelet aggregation in mammals.

  本发明涉及新型二氨基烷基酸衍生物，其可抑制哺乳动物血液中的血小板聚集和血栓形成，因此在预防和治疗与疾病状态相关的血栓形成方面具有用途，例如心肌梗死、中风、周围动脉疾病和弥漫性血管内凝血，并且涉及包括这些化合物的制药组合物以及它们在哺乳动物中抑制血栓形成和血小板聚集的使用。
• US5258398A
  申请人：——

  公开号：US5258398A

  公开（公告）日：1993-11-02
• [EN] ANTITHROMBOTIC DIAMINOALKANOIC ACID DERIVATIVES
  申请人：RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC.

  公开号：WO1993011759A1

  公开（公告）日：1993-06-24

  (EN) This invention relates to novel diaminoalkanoic acid derivatives that inhibit platelet aggregation and thrombus formation in mammalian blood thereby being useful in the prevention and treatment of thrombosis associated with disease states such as myocardial infarction, stroke, peripheral arterial disease and disseminated intravascular coagulation, to pharmaceutical compositions including such compounds, and to their use in inhibiting thrombus formation and platelet aggregation in mammals.(FR) L'invention se rapporte à des nouveaux dérivés d'acide diaminoalcanoïque inhibant l'agrégation des plaquettes et la formation de thrombus dans le sang des mammifères et présentant, de ce fait, une efficacité dans la prévention et dans le traitement de thromboses associées à des états pathologiques, tels que l'infarctus du myocarde, l'apoplexie, l'artéréophatie périphérique et la coagulation intravasculaire disseminée. L'invention se rapporte également à des compositions pharmaceutiques comprenant lesdits composés, ainsi qu'à leur utilisation dans l'inhibition de la formation de thrombus et de l'agrégation de plaquettes chez les mammifères.
• Conformationally flexible platelet aggregation inhibitors based on the tetrapeptide Arg-Gly-Asp-Arg
  作者：SI Klein、M Czekaj、BF Molino、V Chu

  DOI：10.1016/s0223-5234(99)80069-5

  日期：1997.10

  A series of nonpeptide fibrinogen receptor antagonists based upon the tetrapeptide Arg-Gly-Asp-Arg were prepared. These relatively simple derivatives incorporate a high degree of conformational flexibility that was anticipated to allow them to attain the requisite conformation for binding to the platelet fibrinogen receptor. Optimization of the distances between the required acidic and basic functional groups led eventually to compound 7, which is a one hundred-fold more potent inhibitor of platelet aggregation than the peptide it is based upon.